Age and prognosis

What it is

Age is an important prognostic factor in gliomas: younger age is generally associated with a more favorable outlook, while older age tends to be less favorable. This reflects both differences in tumor biology with age and differences in the ability to tolerate intensive treatment. Age is one factor among several.

Understanding Age and prognosis

Across many gliomas, younger patients tend to have better outcomes than older patients. Several reasons contribute: tumor biology can differ with age (for example, IDH-mutant gliomas, which have a better outlook, occur more in younger adults, while IDH-wildtype glioblastoma is more common in older adults), and younger, generally healthier patients may better tolerate intensive treatments. Because of this, age influences both prognosis and treatment decisions — for example, treatment intensity may be adjusted for older or frailer patients to balance benefit and burden (as with hypofractionated radiation). However, age is only one of several prognostic factors (considered with tumor type, grade, molecular features, and performance status), and it influences probabilities at the population level rather than determining any individual's outcome. The care team weighs age in the full context. Understanding age and prognosis in gliomas clarifies how age relates to outlook and treatment.

Why it matters

Understanding age and prognosis helps patients and families see how age relates to a glioma's outlook and treatment — younger age generally being more favorable — while recognizing it is one factor among many and does not determine any individual's course.